ArticleFrontiers in pharmacology2026
Association of decreased CYP2C9 function,
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phenytoin is an anticonvulsant used to treat epilepsy and prevent perioperative seizures. However, genetic prediction of phenytoin-induced cutaneous adverse reactions (PHT-cADRs) and the co-contributing role of non-genetic factors remain unclear. We aimed to evaluate genetic and non-genetic factors associated with PHT-cADRs in a Southern Thai population. Methods: A case-control study was conducted involving 104 patients (26 with PHT-cADRs confirmed by a dermatologist or allergist and 78 phenytoin-tolerant controls). Patient history (demographics, comorbidities, and co-medications) and laboratory parameters (complete blood count and clinical chemistry indicators) during phenytoin initiation were reviewed. Genetic markers including Results: A significant difference in sex was observed among the patients (73.1% female patients in the PHT-cADR group vs. 44.9% in the control group; P = 0.014). Baseline clinical indications differed marginally between the groups; the case group had more neurosurgical patients and fewer patients with epilepsy than the control group. Other non-genetic factors were not significantly associated with PHT-cADRs. For laboratory data, the case group showed significantly lower mean hemoglobin (11.73 g/dL vs. 13.48 g/dL, P = 0.0005) and hematocrit levels (35.94% vs. 40.29%, P = 0.0019) and a higher mean white blood cell count (10.19 × 10 Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.